Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Increasing Expression Of The Efflux Transporter ABCB1 May Predispose CML Cells To Overt TKI Resistance

Laura Eadie, PhD, Timothy P. Hughes, MD, MBBS, Deborah L. White, PhD, FFSc(RCPA)

Blood (2013) 122 (21): 5157.

https://doi.org/10.1182/blood.V122.21.5157.5157

Published: 2013

Journal Articles

The Depth Of In Vivo Kinase Inhibition Achieved Over The First Month Of Nilotinib Therapy Predicts For Subsequent Molecular Response, and Is Closely Related To Nilotinib Plasma Levels

Deborah White, PhD. FFSc (RCPA), Verity Saunders, BScHons, Laura Eadie, PhD, Yeung David, Timothy P. Hughes, MD, MBBS

Blood (2013) 122 (21): 256.

https://doi.org/10.1182/blood.V122.21.256.256

Published: 2013

Journal Articles

Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition

Devendra K Hiwase, MD, MBBS, FRACP, FRCPA, Laura Eadie, Verity Saunders, Timothy Hughes, MD, MBBS, Deborah L. White, PhD

Blood (2010) 116 (21): 3991.

https://doi.org/10.1182/blood.V116.21.3991.3991

Published: 2010

Journal Articles

CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study

Deborah L White, PhD, Verity A Saunders, Phuong Dang, Amity Frede, Laura Eadie, Simona Soverini, PhD, Fabrizio Quarantelli, Peter Lin, Mark Thornquist, Dong-Wook Kim, MD, PhD, Fabrizio Pane, MD, Giovanni Martinelli, Jerald Radich, Thea Kalebic, MD, Giuseppe Saglio, MD, Timothy Hughes, MD

Blood (2008) 112 (11): 3187.

https://doi.org/10.1182/blood.V112.11.3187.3187

Published: 2008

Journal Articles

In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis.

Devendra K. Hiwase, MD, Deborah L. White, Verity A. Saunders, Phuong Dang, Amity Venables, Laura Eadie, Steph Zrim, L. Bik To, MD, Junia V. Melo, MD, Timothy P. Hughes, MD

Blood (2007) 110 (11): 1937.

https://doi.org/10.1182/blood.V110.11.1937.1937

Published: 2007

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Increasing Expression Of The Efflux Transporter ABCB1 May Predispose CML Cells To Overt TKI Resistance

The Depth Of In Vivo Kinase Inhibition Achieved Over The First Month Of Nilotinib Therapy Predicts For Subsequent Molecular Response, and Is Closely Related To Nilotinib Plasma Levels

Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition

CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study

In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis.

Email alerts

ASH Publications

American Society of Hematology

Update search

Increasing Expression Of The Efflux Transporter ABCB1 May Predispose CML Cells To Overt TKI Resistance

The Depth Of In Vivo Kinase Inhibition Achieved Over The First Month Of Nilotinib Therapy Predicts For Subsequent Molecular Response, and Is Closely Related To Nilotinib Plasma Levels

Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition

CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study

In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only